Antibacterials

Synthon Chiragenics, Brigham and Women's Collaborate On Drug Candidates

Published in TB and Outbreaks Week, December 18th, 2001

Synthon Chiragenics Corp. has signed an agreement with The Brigham and Women's Hospital in Boston, Massachusetts to research potential antibacterial candidates to treat highly resistant germs. The collaboration involves preliminary screening of hundreds of antibacterial candidates, which are being developed using one of Synthon's proprietary chemical technologies.

The patented technology was a major breakthrough in working with an important class of molecular compounds called oxazolidonones, which have shown tremendous activity against highly resistant bacteria. Oxazolidonones were used to develop Zyvox, which is the most effective drug on the market today to treat...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry